Biotechnology
Senhwa's Silmitasertib Receives US FDA Orphan Drug Designation for the Treatment of Biliary Tract Cancer
TAIPEI and SAN DIEGO, Jan. 20, 2022 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Des...
2022-01-20 20:00
2023
Nippon Express (Belgium) Acquires GDP Certification for Facility in Brussels Airport's Cargo Area
TOKYO, Jan. 20, 2022 /PRNewswire/ -- Nippon Express (Belgium) N.V./S.A. (hereinafter "NX Belgium"), a company of the Nippon Express Holdings, Inc. Group, has obtained Good Distribution Practice (GDP) certification, effective December 21, 2021, for air and ground forwarding operations, inclusive of...
2022-01-20 15:00
1671
Australia Therapeutic Goods Administration (TGA) Grants Provisional Registration for Novavax COVID-19 Vaccine
Nuvaxovid™ is the first protein-based COVID-19 vaccine to receive approval for provisional registration inAustralia GAITHERSBURG, Md., Jan. 20, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for seri...
2022-01-20 07:29
1490
Neurophth Therapeutics Receives IND Clearance to Initiate Clinical Trial for China AAV-ND4 Gene Therapy NR082 in Leber Hereditary Optic Neuropathy
WUHAN, China and SAN DIEGO, Jan. 19, 2022 /PRNewswire/ -- Neurophth Therapeutics, Inc., (hereinafter referred to as "Neurophth"), today announced receiving the U.S. Food and Drug Administration (FDA) clearance of its investigational new drug (IND) application on thein-vivo gene replacement thera...
2022-01-19 22:30
1854
Qilian International Holding Group Limited Receives Approval for the Sale of its Newly Developed Nitrofurantoin Enteric-coated Tablets
JIUQUAN, China, Jan. 19, 2022 /PRNewswire/ -- Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company", "Qilian International", "we", "our" or "us"), aChina-based pharmaceutical and chemical products manufacturer, today announced that the Company received approval from Gansu Provin...
2022-01-19 20:30
1767
Eluminex Biosciences Acquires Zuretinol Acetate from Retinagenix Holdings
* Purchase of Assets and Related Global Commercialization Rights for Oral 9- cis-Retinol (Zuretinol) for Rare Forms of Childhood Blindness. * Clinical Stage Asset Has Potential for First Approved Oral Therapy for Leber's Congenital Amaurosis (LCA) and Retinitis Pigmentosa (RP) Caused by Mutati...
2022-01-19 19:49
1577
ImmVira's MVR-T3011 IV completed first 2 cohorts dose-escalation of U.S. Phase I clinical study with favorable safety data
SHENZHEN, China, Jan. 18, 2022 /PRNewswire/ -- ImmVira's breakthrough product MVR-T3011 IV, global first clinical-stage oncolytic herpes simplex virus (oHSV) via intravenous injection, has recently completed first 2 cohorts dose-escalation of U.S. Phase I clinical study, and demonstrated good saf...
2022-01-19 08:30
1562
CN Energy Signs Operation & Management Agreement; Enters Multi-Billion Dollar Pharmaceutical Excipients Market
LISHUI, China, Jan. 18, 2022 /PRNewswire/ -- CN Energy Group. Inc. (the "Company") today announced that its subsidiary Hangzhou Forasen Technology Co., Ltd. signed an operation and management ("O&M") agreement (the "Agreement") with HuaiNan JiaHe New Materials Co., Ltd. ("JiaHe") and JiaHe's acti...
2022-01-18 21:00
1641
Akeso's AK117 (CD47 monoclonal antibody) in Combination with AK112 (PD-1/VEGF bi-specific antibody) to Initiate a Phase Ib/II Clinical Trial with or without Chemotherapy for the Treatment of Advanced Malignant Tumors
HONG KONG, Jan. 18, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) announces that Ligufalimab (CD47 monoclonal antibody, research and development code: AK117), the novel immuno-oncology drug independently developed by the Company, combined with Ivonescimab (PD-1/VEGF bi-specific antibody, research an...
2022-01-18 20:44
2031
MindRank Begins IND-enabling Studies of its first AI-designed Drug, 8 Months After Program Initiation
HANGZHOU, China, Jan. 18, 2022 /PRNewswire/ -- MindRank AI, an artificial intelligence (AI) driven biotech company, today announced that the company has nominated a preclinical candidate (PCC) for an important class B GPCR drug target, 8 Months After Program Initiation. Historically, the developm...
2022-01-18 17:17
1432
WuXi Biologics Completes GMP Inspection by South Korea's Ministry of Food and Drug Safety for Drug Substance Facility
* WuXi Biologics completes the first GMP inspection in 2022, demonstrating the company's premier quality system is in full compliance with global regulatory requirements. WUXI, China, Jan. 17, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access ...
2022-01-18 10:50
2135
Abbisko Therapeutics Announces Worldwide Collaboration with Lilly to Discover and Develop Novel Molecules
SHANGHAI, Jan. 17, 2022 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter), a subsidiary of Abbisko Cayman Limited (Stock Code: 2256.HK), today announced that it has entered into a worldwide collaboration and exclusive licensing agreement (the "Agreement") with Eli ...
2022-01-18 10:41
2156
CARsgen Appoints Richard John Daly as the President of CARsgen Therapeutics Corporation
SHANGHAI and DURHAM, N.C., Jan. 17, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company mainly focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced today the appointment ofRichard John Daly ("M...
2022-01-17 21:50
2362
Jacobio Receives IND Approval for Aurora A Inhibitor JAB-2485 from FDA
BEIJING and SHANGHAI and BOSTON, Jan. 16, 2022 /PRNewswire/ -- Jacobio's self-developed global first-in-class drug Aurora A inhibitor JAB-2485 received IND (Investigational New Drug) from the FDA (Food and Drug Administration) in US. Jacobio plans to initiate a Phase I/IIa clinical trial in pati...
2022-01-17 09:04
1445
Samsung Biologics Shares Strategic Roadmap for Sustainable Growth at the 40th Annual JP Morgan Healthcare Conference
INCHEON, South Korea, Jan. 12, 2022 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) announced its sustainable growth plan for this year at the 2022 Annual JP Morgan Healthcare Conference, which is held virtually fromJanuary 10th to 13th with leaders from major pharmaceutical and biopharmaceuti...
2022-01-13 08:52
1973
Alar Announces Significant Progress on Developing Long-acting Buprenorphine Injectable ALA-1000
* Single-ascending-dose (SAD) study successfully demonstrated the safety, tolerability, and sustained release profile at least 3 months resulting from ALA-1000 injection in patients with opioid dependence. TAICHUNG, Taiwan, Jan. 12, 2022 /PRNewswire/ -- Alar Pharmaceuticals Inc. (Alar, TWSE:678...
2022-01-13 00:00
2104
I-Mab Announces First Patient Dosed in China Phase 2 Clinical Trial of Efineptakin Alfa in Combination with Pembrolizumab in Advanced Solid Tumors
SHANGHAI and GAITHERSBURG, Md., Jan. 12, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the first patient had been dosed in itsChina phase...
2022-01-12 21:00
1665
Gracell Biotechnologies Unveils Innovation Center in U.S.
SUZHOU, China and PALO ALTO, Calif., Jan. 12, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell" or the "Company"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, toda...
2022-01-12 21:00
1459
Ascentage Pharma Presented at the 40th Annual J.P. Morgan Healthcare Conference Reporting Steady Transition Towards a Full-Fledged Biopharma
SUZHOU, China and ROCKVILLE, Md., Jan. 11, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that Dr.Dajun Yang, the company's Chairman and CEO...
2022-01-12 10:19
2318
Shanghai ZhenGe Biotech Raises USD 100 million Round C Led by Goldman Sachs Asset Management and Sofina
SHANGHAI, Jan. 11, 2022 /PRNewswire/ -- Shanghai ZhenGe Biotech Co., Ltd. ("ZhenGe Biotech" or "the Company") announced the completion of round C financing of US$100 million, led by Goldman Sachs Asset Management and Sofina. Also investing were Novo Holdings A/S, Qiming Venture Capital, IDG Capit...
2022-01-11 22:15
6594
Week's Top Stories
Most Reposted
Star-Studded Sponsor Line-up Takes Centre Court at the Singapore Tennis Open 2025
[Picked up by 291 media titles]
2025-01-28 10:49
Sephora Unveils Its First Film, "Beauty & Belonging" Celebrating Diversity and Authenticity
[Picked up by 288 media titles]
2025-01-24 08:00
Dahua Technology Joins Hands with WWF to Expand Sustainability Efforts Globally
[Picked up by 270 media titles]
2025-01-24 12:15
HZICC: Linping Manufacturing Goes Global to Promote City Brand
[Picked up by 266 media titles]
2025-01-24 22:59Sushui Tech to Launch New DMFC Products at Smart Energy Week, Tokyo 2025
[Picked up by 259 media titles]
2025-01-28 09:53
Most Read
BRI UMKM EXPO(RT) 2025 Returns: Showcasing Local Products to the World
2025-01-25 15:38
8143
U Power Announces Pricing of $5.0 Million Registered Direct Offering
2025-01-24 22:18
5594